Patrys
ASX:PATNedlands, Australia· Est.
Patrys leverages a reformulated quetiapine IV and a novel deoxymab platform to address unmet needs in delirium and oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Patrys leverages a reformulated quetiapine IV and a novel deoxymab platform to address unmet needs in delirium and oncology.
OncologyImmunologyNeurology
Technology Platform
Deoxymab antibodies – a novel antibody scaffold engineered for enhanced tissue penetration and NETosis targeting; plus an IV reformulation of quetiapine for acute delirium.
Opportunities
RLS‑2202 addresses a large, unmet delirium market with a rapid‑development, low‑risk reformulation strategy; deoxymabs open a novel therapeutic class across oncology and autoimmune diseases.
Risk Factors
Regulatory uncertainty for the IV quetiapine pathway and translational risk of NETosis‑targeted antibodies could delay clinical milestones and increase capital needs.
Competitive Landscape
Limited competition in IV quetiapine for delirium; deoxymab platform differentiates from conventional antibodies through unique NETosis targeting, though it faces competition from other next‑gen antibody and protein therapeutics.